thestreet.com — BOSTON (TheStreet) -- New drugs from Pfizer and GlaxoSmithKline that precisely target genetic weaknesses in cancer were given spotlight treatment Wednesday night by the American Society of Clinical Oncology (ASCO) in a preview of its upcoming and closely followed annual meeting. ASCO officials also highlighted a mid-stage study of Johnson & Johnson's Zytiga in early-stage (pre-surgical) prostate cancer patients.